Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review
Introduction To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the ris...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2502643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032427110498304 |
|---|---|
| author | Kelvin McKoy Stephanie Campbell Patricia Novy Robert S. Janssen |
| author_facet | Kelvin McKoy Stephanie Campbell Patricia Novy Robert S. Janssen |
| author_sort | Kelvin McKoy |
| collection | DOAJ |
| description | Introduction To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the risk of chronic HBV infection, cirrhosis, liver cancer, and death from liver-related disease among coinfected individuals.Areas covered This review explores recent research on the two-dose HepB-CpG (HEPLISAV-B) vaccine, which is a potential solution to the challenge of suboptimal immune responses to three-dose HBV vaccines (HepB-alum) in people living with HIV (PLWH). We compare the immunogenicity and safety of HepB-CpG in both vaccine-naive and previously vaccinated nonresponding PLWH populations.Expert opinion Compared with three-dose HepB-alum vaccines, HepB-CpG offers a more convenient two-dose schedule, which could increase series completion rates. HepB-CpG might be more immunogenic in vaccine-naive and vaccine-experienced PLWH. Both attributes make HepB-CpG a possible future standard of care for adult HBV vaccination in PLWH. |
| format | Article |
| id | doaj-art-8b60aaa1e8464e8da06519343ac7530a |
| institution | DOAJ |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-8b60aaa1e8464e8da06519343ac7530a2025-08-20T02:58:38ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0124136537210.1080/14760584.2025.2502643Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative reviewKelvin McKoy0Stephanie Campbell1Patricia Novy2Robert S. Janssen3Dynavax Technologies Corporation, Emeryville, CA, USADynavax Technologies Corporation, Emeryville, CA, USADynavax Technologies Corporation, Emeryville, CA, USADynavax Technologies Corporation, Emeryville, CA, USAIntroduction To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the risk of chronic HBV infection, cirrhosis, liver cancer, and death from liver-related disease among coinfected individuals.Areas covered This review explores recent research on the two-dose HepB-CpG (HEPLISAV-B) vaccine, which is a potential solution to the challenge of suboptimal immune responses to three-dose HBV vaccines (HepB-alum) in people living with HIV (PLWH). We compare the immunogenicity and safety of HepB-CpG in both vaccine-naive and previously vaccinated nonresponding PLWH populations.Expert opinion Compared with three-dose HepB-alum vaccines, HepB-CpG offers a more convenient two-dose schedule, which could increase series completion rates. HepB-CpG might be more immunogenic in vaccine-naive and vaccine-experienced PLWH. Both attributes make HepB-CpG a possible future standard of care for adult HBV vaccination in PLWH.https://www.tandfonline.com/doi/10.1080/14760584.2025.2502643CpG 1018 adjuvanthepatitis B virusHepB-alumHepB-CpGHEPLISAV-Bimmunogenicity |
| spellingShingle | Kelvin McKoy Stephanie Campbell Patricia Novy Robert S. Janssen Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review Expert Review of Vaccines CpG 1018 adjuvant hepatitis B virus HepB-alum HepB-CpG HEPLISAV-B immunogenicity |
| title | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review |
| title_full | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review |
| title_fullStr | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review |
| title_full_unstemmed | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review |
| title_short | Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review |
| title_sort | hepatitis b vaccination with hepb cpg in people living with hiv a narrative review |
| topic | CpG 1018 adjuvant hepatitis B virus HepB-alum HepB-CpG HEPLISAV-B immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2502643 |
| work_keys_str_mv | AT kelvinmckoy hepatitisbvaccinationwithhepbcpginpeoplelivingwithhivanarrativereview AT stephaniecampbell hepatitisbvaccinationwithhepbcpginpeoplelivingwithhivanarrativereview AT patricianovy hepatitisbvaccinationwithhepbcpginpeoplelivingwithhivanarrativereview AT robertsjanssen hepatitisbvaccinationwithhepbcpginpeoplelivingwithhivanarrativereview |